Prime Medicine Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
PRME$3.90-9.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders Equity for the
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Common Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveLosses · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · Shares · Amount | ||||||
| Balance as of December 31, 2024 | 131,160,842 | $2 | $840,358 | $1 | $(687,212) | $153,149 |
| Stock-based compensation expense | — | — | 5,681 | — | — | 5,681 |
| Change in unrealized loss on investments, net of tax | — | — | — | (16) | — | (16) |
| Net loss | — | — | — | — | (51,890) | (51,890) |
| Balance as of March 31, 2025 | 131,160,842 | $2 | $846,039 | $(15) | $(739,102) | $106,924 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| Common Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveLosses · AccumulatedDeficit · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · Shares · Amount | ||||||
| Balance as of December 31, 2023 | 97,377,121 | $2 | $624,414 | $(15) | $(491,330) | $133,071 |
| Issuance of common stock from public offering, net of issuance costs of $8.9 million | 22,560,001 | — | 132,055 | — | — | 132,055 |
| Issuance of pre-funded warrants, net of issuance costs of $1.2 million | — | — | 18,800 | — | — | 18,800 |
| Issuances of common stock under the employee stock purchase plan | 74,488 | — | 436 | — | — | 436 |
| Issuance of common stock upon exercise of stock options | 9,664 | — | 36 | — | — | 36 |
| Stock-based compensation expense | — | — | 5,209 | — | — | 5,209 |
| Change in unrealized loss on investments, net of tax | — | — | — | (80) | — | (80) |
| Net loss | — | — | — | — | (45,761) | (45,761) |
| Balance as of March 31, 2024 | 120,021,274 | 2 | 780,950 | (95) | (537,091) | 243,766 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.